Men of various racial and ethnic backgrounds are affected by prostate cancer, which is the fifth largest cause of cancer-related death in men. Cancer development and metastasis have been linked to specific genetic alterations. People may carry genetic variants that make prostate cancer more likely, such as changes in genes that are related to testosterone metabolism, and genetic mutations can also tell clinicians and researchers more about a patient’s disease. In the targeted therapy of prostate cancer, certain genetic alterations can be exploited as biomarkers.For patients in Sweden, screening that identifies mutations in DNA from tumors found in circulation may now become routine in the treatment of metastatic prostate cancer.